An extract from Salvia officinalis (Sage) leaves showed antimicrobial activity against vancomycin-resistant enterococci (VRE). We isolated the effective compound and identified it as oleanolic acid, a triterpenoid. We also tested antimicrobial activity of similar triterpenoids, ursolic acid, uvaol, betulinic acid and betulin. We found that ursolic acid also showed antimicrobial activity against VRE. The minimum inhibitory concentrations (MICs) of oleanolic acid and ursolic acid were 8 and 4 m mg/ml, respectively. These two compounds also showed antimicrobial activity against Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus (MRSA). These compounds showed bactericidal activity against VRE at least for 48 h when added at concentrations that were two-times higher than their MICs.
The infectious diseases caused by multidrug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP) and vancomycin-resistant enterococci (VRE), are very serious problems because these bacteria are resistant to a number of antimicrobials in many cases. They are Grampositive cocci, and infections caused by them are becoming very serious problems throughout the world. MRSA was first reported in the U.K. in 1961 and then spread world-wide. From CDC reports, the rate of MRSA in S. aureus detected from intensive care unit (ICU) patients in 2003 in the United States was more than 60%, and it increased annually (http://www.cdc.gov/ncidod/hip/ARESIST/ICU_MRSA.pdf). In Japan, there are more than 20000 reported cases of MRSA infections per year (http://idsc.nih.go.jp/idwr/index.html). Vancomycin is one of a few effective drugs for MRSA infections. However, vancomycin-resistant S. aureus (VRSA) was first reported in 2002 in the United States. 1) Thus, effective antimicrobials for treatment of patients infected with VRSA are very limited. S. pneumoniae is one of the most important pathogens for community acquired pneumonia, meningitis, and otitis media. PRSP was first reported in Australia in 1967, 2) and drug-resistant S. pneumoniae (DRSP) which is resistant to several antimicrobials was first reported in South Africa in 1977.
3) Cases of infection with S. pneumoniae that are resistant not only against b-lactams but also against other antimicrobials such as macrolides and fluoroquinolones have been reported to be increasing. 4) VRE has been first reported in U.K. and France in 1986. 5) In the case of the United States, the percentage of VRE in enterococci isolated from ICUs was 0.4% in 1989, but it increased up to 28.5% in 2003. 6, 7) Of the strains belonging to the enterococcal species, Enterococcus faecalis and E. faecium are common isolates from human infections. 8) Among the isolates of enterococcal species, E. faecalis accounts for 80-90% and the rest is mainly E. faecium.
9) E. faecium is more resistant against many antimicrobials than any other enterococcal species. 10) There are many cases of infection by drug resistant bacteria whereas few drugs are available effective for the treatment of such patients. Thus, it is urgently necessary to discover or develop new drugs that are effective on such drug resistant bacteria. We have been trying to discover novel compounds, such as antimicrobial compounds and inhibitors of drug resistance systems in bacteria, [11] [12] [13] [14] [15] that are effective against multidrug-resistant bacteria.
Though Salvia officinalis (sage) is known as one of the herbs that has antimicrobial activity, there are few papers that have showed its antibacterial activity. We found that a crude extract of sage leaves showed antimicrobial activity against VRE. Thus, we tried to purify and determine the structure of the effective compound. Arakawa (National Institute of Infectious Diseases). Clinical isolates of MRSA strains OM481 and OM584 were from Okayama University Hospital. Streptococcus pneumoniae R6 (ATCC BAA-255) was purchased from American Type Culture Collection (ATCC). Escherichia coli K12 and Pseudomonas aeruginosa PAO1 were also used in this study.
MATERIALS AND METHODS

Bacterial Strains
Drug Susceptibility Testing Minimum inhibitory concentrations (MICs) of various drugs were determined as described previously 13) with cells of VRE, MRSA, P. aeruginosa, E. coli, S. marcescens and S. pneumoniae. For cells of S. pneumoniae, Mueller-Hinton broth supplemented with strepto haemo supplement 'Eiken' was used.
Isolation of Effective Compounds Dried and ground leaves of S. officinalis (850 g) were extracted with 70% aqueous acetone at room temperature; the acetone extract was concentrated by using a rotary evaporator to give 300 g of dry sample. A half of the sample was dissolved with water and extracted with ethyl acetate (AcOEt). The AcOEt extract was concentrated and then dried by using N 2 gas, and 70 g of sample was obtained. This AcOEt extract was subjected to column chromatography over DIAION HP-20 (MitsubishiKagaku Co.) and eluted with aqueous methanol (70, 80, 90, 100%) in a stepwise manner, and with 100% acetone at the final step. Since the eluate with 100% methanol showed the highest antimicrobial activity against VRE, 5 g of the 100% methanol fraction was further subjected to column chromatography over Sephadex LH-20 (Amersham Biosciences Co.) by using 100% ethanol as a solvent. Fractions that showed the highest antimicrobial activity were collected (500 mg). The dried material (60 mg) was subjected to highpressure liquid chromatography (HPLC) with Inertsil ODS-3 (1 by 25 cm column, GL Science Co.) using 90% acetonitrile as an eluant, and 8 mg of the most effective compound was isolated. The structure of the isolated compound was elucidated by 1 H-, 13 C-NMR and MS spectra and identified as oleanolic acid. We repeated the purification step using HPLC, and obtained enough oleanolic acid for our experiments.
Materials The leaves of S. officinalis, triterpenoids other than oleanolic acid, and chemicals used in this study were purchased from commercial sources.
RESULTS AND DISCUSSION
MICs of Triterpenoids
The acetone extract from sage obtained at the first step showed very weak antimicrobial activity, and the MIC of the extract against VRE was 256-512 mg/ml. We purified the active compound and identified it as oleanolic acid. The MICs of oleanolic acid, and other triterpenoids which have been reported to be contained in sage extract 15) against various bacteria, are shown in Table 1 . The MIC values of oleanolic acid and ursolic acid against VRE were 8 mg/ml and 4 mg/ml, respectively. These MIC values are fairly low as constituents of plants. In other words, antimicrobial activity of these compounds is fairly high among compounds derived from plants. Both of them also showed antimicrobial activity against other Gram-positive cocci such as MRSA and S. pneumoniae ( Table 1 ). The MIC of oleanolic acid was 16 mg/ml for S. pneumoniae R6 and S. aureus OM481 (MRSA), and 32 mg/ml for S. aureus OM584 (MRSA). The MIC of ursolic acid was 8 mg/ml for S. pneumoniae R6 and S. aureus OM481, and 16 mg/ml for S. aureus OM584. On the other hand, neither compound showed antimicrobial activity against Gram-negative bacteria tested (MICs were >128 mg/ml). The antimicrobial activity of ursolic acid on VRE, S. pneumoniae and MRSA strains were two times stronger than those of oleanolic acid judging from the MIC values. Uvaol, betulinic acid and betulin did not show significant antimicrobial activity against VRE, S. pneumoniae and MRSA (MICs were >128 mg/ml). We compared the antibacterial activities between these compounds and ampicillin, a b-lactam antibiotic. Both ursolic acid and uvaol showed stronger activity than ampicillin on E. faecium and MRSA strains used in this study, and similar activity on E. faecalis strains used (Table 1) .
Although Woldemichael et al. previously described the antimicrobial properties of oleanolic acid against S. aureus and Bacillus subtilis, 17) our paper is the first report on its antimi- According to their results, since the MIC against E. faecalis was 75-500 mg/ml, the antibacterial effect was weak. 18) Those MIC values are different from our data (4-8 mg/ml) by 2 to 3 orders of magnitude. Their antibacterial activity was specific to enterococci and S. pneumoniae. It seems that such differences are due to differences in assay conditions and in strains used. Other activities of both compounds have been also reported, such as, for example, anti-inflammatory activity, 19) anti-hyperlipidemic activity, anti-tumor-promotion activity and hepatoprotective effects, and so on. 20) One group has reported that betulinic acid showed antimicrobial activity against S. aureus, 21) whereas another group reported that it did not. 22) Our data support the latter result. We tested the effects of oleanolic acid and ursolic acid on E. coli, P. aeruginosa and S. marcescens, a Gram-negative bacterium. However, these two compounds did not show significant antibacterial activity (Table 1 ). Multidrug efflux pumps play an important role in intrinsic drug resistance in E. coli and P. aeruginosa. Therefore, we also tested the effects of oleanolic acid and ursolic acid on mutants of E. coli and P. aeruginosa, both mutants of which are drug hyper-susceptible due to their lack of major multidrug efflux pumps. MICs of oleanolic acid and ursolic acid were higher than 128 mg/ml with such hyper-susceptible mutants (data not shown). Although we tested concentrations higher than 256 mg/ml, a precipitate was formed at such higher concentrations. Thus, it is not clear whether these compounds become substrates for multidrug efflux pumps. Anyway, we conclude that oleanolic acid and ursolic acid are not effective on Gram-negative bacteria, perhaps due to the presence of the outer membrane. We also tested antifungal activity with Candida albicans, and found that the MICs of oleanolic acid and ursolic acid were higher than 128 mg/ml (data not shown).
Since oleanolic acid and ursolic acid showed fairly high antimicrobial activity on VRE, we investigated whether activity of oleanolic acid and ursolic acid was bactericidal or bacteriostatic (Fig. 2) . Oleanolic acid showed bactericidal activity on E. faecium BM4147 when added to the culture medium at concentrations higher than 16 mg/ml (2 times MIC) for 48 h. However, when 8 mg/ml of oleanolic acid (same as MIC) was added, bactericidal activity continued for 12 h, and cells started to grow after 24 h. Ursolic acid showed almost the same effects on E. faecium BM4147 (data not shown). Similar results were obtained with oleanolic acid and E. faecalis, but it seemed that the bactericidal activity was slightly weaker compared with that on E. faecium (data not shown). On the other hand, ursolic acid showed bacteriostatic activity on E. faecalis at concentrations higher than 8 mg/ml (2 times MIC) (data not shown).
The antimicrobial activity of oleanolic acid or ursolic acid is not so strong as compared with antimicrobial drugs that are clinically used, although oleanolic acid and ursolic acid showed fairly high activity. Nonetheless, it seems that both compounds are not so toxic. In fact, oleanolic acid has been successfully used as an orally administered drug to treat human liver diseases in China. 20) Thus, they might be used for the treatment of infections by VRE. Fig. 2 . Effect of Oleanolic Acid on Viable Cell Number of VRE E. faecium BM4147 cells grown in Brain-Heart Infusion broth were diluted with fresh medium and incubated at 37°C under aerobic conditions in the absence (ᮀ) or presence of oleanolic acid at 8 mg/ml (᭜), 16 mg/ml (᭹), or 32 mg/ml (᭡). Samples were taken at the indicated time points, and viable cell numbers (colony forming unit: CFU) were counted after growth on plates.
